• Novel therapeutic approach: PK007 is a selective hematopoietic prostaglandin D2 synthase (HPGDS) inhibitor targeting Duchenne Muscular Dystrophy (DMD). Here, PTGDS is linked to Duchenne muscular dystrophy.